vTv Therapeutics Inc VTVT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
24.99quote price arrow up+0.84 (+3.48%)
Volume
3,315
52 week range
7.38 - 39.60
Loading...
  • Open24.00
  • Day High24.96
  • Day Low24.00
  • Prev Close24.15
  • 52 Week High39.60
  • 52 Week High Date06/01/23
  • 52 Week Low7.38
  • 52 Week Low Date01/26/24

Key Stats

  • Market Cap75.225M
  • Shares Out3.01M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta0.57
  • YTD % Change115.13

KEY STATS

  • Open24.00
  • Day High24.96
  • Day Low24.00
  • Prev Close24.15
  • 52 Week High39.60
  • 52 Week High Date06/01/23
  • 52 Week Low7.38
  • 52 Week Low Date01/26/24
  • Market Cap75.225M
  • Shares Out3.01M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta0.57
  • YTD % Change115.13

RATIOS/PROFITABILITY

  • EPS (TTM)-9.79
  • P/E (TTM)-2.55
  • Fwd P/E (NTM)-83.30
  • EBITDA (TTM)-25.412M
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-306,833.31%
  • Debt To Equity (MRQ)-0.77%

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On vTv Therapeutics Inc

 

Content From Our Affiliates

Profile

MORE
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an...
Paul Sekhri
President, Chief Executive Officer, Director
Steven Tuch
Chief Financial Officer
Barry Brown
Chief Accounting Officer
Richard Nelson
Executive Vice President - Corporate Development, Director
Address
3980 Premier Dr, Suite 310
High Point, NC
27265
United States

Top Peers

SYMBOLLASTCHG%CHG
ALRN
Aileron Therapeutics Inc
5.00+0.75+17.65%
ENLV
Enlivex Therapeutics Ltd
1.40-0.08-5.41%
NGNE
Neurogene Inc
31.58-2.06-6.12%
BIVI
BioVie Inc
0.4884+0.017+3.6063%
ACXP
Acurx Pharmaceuticals Inc
2.13+0.33+18.33%